SCHEMBL5115440

SCHEMBL5115440

c1ccc(-c2cccc(Oc3cccc(N(c4ccccc4)c4ccccc4)n3)n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.46
KMT2A Q03164 4/20 0.46
MEN1 O00255 3/20 0.46
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
KCNH2 Q12809 1/20 0.40
ASIC3 Q9UHC3 1/20 0.40
NPC1 O15118 3/20 0.34
TDP1 Q9NUW8 2/20 0.34
MAPK1 P28482 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HTR1A P08908 1/20 0.33
DRD2 P14416 1/20 0.33
HTR2A P28223 1/20 0.33
HTR7 P34969 1/20 0.33
ALDH1A1 P00352 5/20 0.32
FFAR4 Q5NUL3 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14032343 0.88 ALDH1A1 (0.38) RAB9ANPC1TDP1CYP1A2CYP2C9
SCHEMBL5103779 0.83 MEN1 (0.65) RAB9AKMT2AMEN1SLC6A2SLC6A4
SCHEMBL5115890 0.82 MEN1 (0.59) RAB9AKMT2AMEN1ASIC3NPC1
SCHEMBL5115896 0.81 MEN1 (0.58) RAB9AKMT2AMEN1ASIC3NPC1
SCHEMBL5109003 0.75 TDP1 (0.42) RAB9AKMT2AMEN1ASIC3NPC1
SCHEMBL23350932 0.75 L3MBTL1 (0.36) RAB9ANPC1TDP1MAPK1CYP1A2
SCHEMBL18335708 0.74 RAB9A (0.58) RAB9AKMT2AMEN1SLC6A2SLC6A4
SCHEMBL13231072 0.74 MEN1 (0.44) RAB9AKMT2AMEN1ASIC3TDP1
SCHEMBL14655723 0.73 MEN1 (0.47) RAB9AKMT2AMEN1ASIC3NPC1
SCHEMBL17032805 0.73 ALDH1A1 (0.46) RAB9AKMT2AMEN1NPC1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1683804-B1 PLATINUM COMPLEX AND LUMINESCENT ELEMENT TAKASAGO PERFUMERY CO LTD (JP) 2013-07-31 EP disclosed
EP-1683804-B1 PLATINUM COMPLEX AND LUMINESCENT ELEMENT TAKASAGO PERFUMERY CO LTD (JP) 2013-07-31 EP disclosed
US-7442797-B2 Platinum complex and light emitting device TAKASAGO INTERNATIONAL CORPORATION (JP) 2008-10-28 US disclosed
US-7442797-B2 Platinum complex and light emitting device TAKASAGO INTERNATIONAL CORPORATION (JP) 2008-10-28 US disclosed
US-7442797-B2 Platinum complex and light emitting device TAKASAGO INTERNATIONAL CORPORATION (JP) 2008-10-28 US disclosed
US-20070103060-A1 Platinum complex and light emitting device TAKASAGO INTERNATIONAL CORPORATION (JP) 2007-05-10 US disclosed
US-20070103060-A1 Platinum complex and light emitting device TAKASAGO INTERNATIONAL CORPORATION (JP) 2007-05-10 US disclosed
US-20070103060-A1 Platinum complex and light emitting device TAKASAGO INTERNATIONAL CORPORATION (JP) 2007-05-10 US disclosed
EP-1683804-A2 PLATINUM COMPLEX AND LUMINESCENT ELEMENT Takasago International Corporation (JP) 2006-07-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070103060-A1 Platinum complex and light emitting device UBE2D3, PCID2, CCND2 RAB9A 1399/4885KMT2A 1827/4885MEN1 1473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.